Secondary Progressive Multiple Sclerosis With Inflammatory Disease ActivitySWISSMASIANCT04895202
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
An observational study of Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity, run by Novartis Pharmaceuticals at 6 sites in Switzerland.
Trial summary
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
- What is being tested?
- Siponimod
- How many people
- 8 participants
- Where
- 6 sitesSwitzerland
- Study dates
- 19 Nov 2021to 20 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: SPMS population in Switzerland who are treated with Siponimod as per Swiss label
Who may be able to join
- Signed informed consent
- Adult patients with a documented diagnosis of SPMS with inflammatory disease activity who are going to be treated with Siponimod under routine medical care and in accordance with the Swiss label
- Patient willing and able to complete the questionnaires
Who cannot join
- Patients treated outside of the approved Swiss label for Siponimod
- Prior treatment or already ongoing treatment with Siponimod
- Use of investigational drugs during the study, OR within 3 months before enrollment, OR within 5 half-lives of investigational drug before enrollment, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer
- Subjects who are not able to provide consent due to incapable judgement
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
Switzerland6 sites
Novartis Investigative Site
Basel, 4031
Novartis Investigative Site
Bern, 3010
Novartis Investigative Site
Lugano, 6900
Novartis Investigative Site
Winterthur, 8400
Novartis Investigative Site
Zug, Canton of Zug, 6300
Novartis Investigative Site
Zurich, Canton of Zurich, 8006
About this study
Official title: Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label.
Read the detailed description
Primary data will be collected during an observational period of three years of Siponimod treatment. Additionally, medical history of participants will be collected including EDSS, MRI outcomes, relapses and previous medication to allow the estimation of Siponimod treatment effects on an individual basis. It is planned to include an optional blood draw for a later biomarker analysis.
- Being tested
- Siponimod
- Keywords
- SPMS, secondary progressive multiple sclerosis, Siponimod, active disease, inflammatory disease activity, disability progression
- Medical subject headings
- Multiple Sclerosis, Chronic Progressive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SiponimodOther
Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
| Study group | Role | What they receive |
|---|---|---|
| Siponimod | Patients administered Siponimod as per Swiss label Receives: Other: Siponimod |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of expanded disability status scale (EDSS)
The EDSS score is a widely used tool for determining the degree of disability in MS at any point in time. The EDSS value is generated based on overall impression and individual scores of the following functional systems: cognition, mood, fatigue, vision, brain stem, upper extremities, lower extremities, bladder and bowel function, sexuality. This results in a scale from 0 (healthy) to 10 (death from MS)
Measured: Baseline, month 36
Secondary outcomes (7)
Proportion of patients with six month confirmed disability progression (CDP) by expanded disability status scale (EDSS)
Disability progression based on the EDSS score is defined as a 1 point increase from baseline in patients with a baseline score of ≤ 5, or a 0.5 point increase in patients with a baseline score of ≥5.5. As part of a secondary endpoint to this study, the deterioration of the EDSS of ≥1 point (baseline EDSS ≤ 5) or 0.5 points (baseline EDSS ≥5.5) must be confirmed after 6 months. This is called 6-month confirmed progression (6M-CDPEDSS). EDSS values to confirm progression must not be determined during an attack. The maximum duration of an attack is limited to 90 days
Measured: month 36
Proportion of patients with six month confirmed disease progression by symbol digit modalities test (SDMT)
The SDMT is a sensitive and specific test for examining attention, concentration and information processing speed, which are typically impaired in cognitively impaired MS patients.
The patients receive an SDMT test sheet. At the beginning of this sheet there are 9 numbers paired with 9 associated individual symbols. Below that are further lines with symbols and empty boxes. The patients must now verbally assign the correct numbers to the symbols as quickly as possible. Exercise examples are given at the beginning of the test which are not taken into account when evaluating the test. The number of correctly assigned items within 90 seconds results into the test score. The total duration of the test is about 5 minutes.
SDMT: ≥4.0-point confirmed worsening from baseline score sustained for at least 6 months respectively
Measured: Up to 36 months
Treatment effect of Siponimod on walking speed as measured by the timed 25 foot walk test (T25FWT)
The T25-FW is an objective and quantitative test of the lower extremities (Motl et al., 2017). This stops the time in seconds that a patient needs to walk 25 feet (7.62 m). The patient should walk as quickly and safely as possible. This test is carried out twice in succession and the mean value of the time required is documented in seconds. An improvement or deterioration of 20% is seen as a clinical meaningful change (Motl et al., 2017).
Measured: Baseline, up to 36 months
Treatment effect of Siponimod on quality of life based on EQ-5D
The EQ-5D patient questionnaire is a generic multidimensional measuring instrument for describing health-related quality of life (EuroQol, 1999). The five domains mobility, ability to take care of oneself, everyday activities, pain / discomfort and anxiety / depression are considered. For the individual dimensions, the most appropriate answer from three given options is selected (1 = no problem, 2 = moderate problem, 3 = major problem). In addition, the patient marks the current state of health on a scale from 0 (worst-conceivable state of health) to 100 (best-conceivable state of health).
Measured: Baseline, month 36
Treatment effect of Siponimod on fatigue measured by Fatigue Scale for Motor and Cognitive Functions (FSMC)
The FSMC is a patient questionnaire to clarify cognitive and motor fatigue, a typical symptom of MS (Penner et al., 2009). With the help of the FSMC, a cognitive, a motor, and a total score are determined. Increased scores indicate higher impairment caused by fatigue.
A 5-point scale (ranging from 'does not apply at all' to 'applies completely') produces a score between 1 and 5 for each scored question.
Measured: Baseline, month 36
Treatment effect of Siponimod on fatigue measured by Beck's depression inventory (BDI)
BDI is a patient questionnaire for measuring the severity of depression (Beck, 1972). Depression is a common symptom in MS and can cause fatigue. With the BDI test we assess the frequency of depression and its correlation to fatigue. This results in a scale from 0 to 63. The level of depression is evaluated according to the table below:
- 0-13: no or minimal symptoms
- 14-19: mild symptoms
- 20-28: moderate symptoms
- 29-63: severe depressive symptoms
Measured: Baseline, month 36
Treatment effect of Siponimod on fatigue measured by Epworth sleepiness scale (ESS) questionnaire
ESS is a patient questionnaire to measure daytime sleepiness (Ibanez et al, 2017). Results of the ESS will allow to correlate whether observed fatigue might be attributed to daytime sleepiness. The level of sleepiness is evaluated according to the table below:
0-5 Lower Normal Daytime Sleepiness 6-10 Higher Normal Daytime Sleepiness 11-12 Mild Excessive Daytime Sleepiness 13-15 Moderate Excessive Daytime Sleepiness 16-24 Severe Excessive Daytime Sleepiness
Measured: Baseline, month 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2021
- Study start19 Nov 2021
- Primary completion20 Dec 2022
- Study completion20 Dec 2022
Why it stopped: Insufficient patient recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Secondary Progressive Multiple Sclerosis With Inflammatory Disease ActivityStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceiticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04895202
- Sponsor's protocol ID
- CBAF312ACH01
- Acronym
- SWISSMASIA
- Status last verified
- Aug 2023
- First submitted
- 17 May 2021
- Last updated
- 29 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study
- ClinicalTrials.gov ID
- NCT04895202
- Acronym / sponsor ID
- SWISSMASIA / CBAF312ACH01
- Keywords
- SPMS, secondary progressive multiple sclerosis, Siponimod, active disease, inflammatory disease activity, disability progression
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Insufficient patient recruitment
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 19 Nov 2021 (actual)
- Primary completion
- 20 Dec 2022 (actual)
- Study completion
- 20 Dec 2022 (actual)
- First posted
- 20 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod as per Swiss label.
Detailed description
Primary data will be collected during an observational period of three years of Siponimod treatment. Additionally, medical history of participants will be collected including EDSS, MRI outcomes, relapses and previous medication to allow the estimation of Siponimod treatment effects on an individual basis. It is planned to include an optional blood draw for a later biomarker analysis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Siponimod | – | Other: SiponimodPatients administered Siponimod as per Swiss label |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- SPMS population in Switzerland who are treated with Siponimod as per Swiss label
Key inclusion criteria (3 listed)
- Signed informed consent
- Adult patients with a documented diagnosis of SPMS with inflammatory disease activity who are going to be treated with Siponimod under routine medical care and in accordance with the Swiss label
- Patient willing and able to complete the questionnaires
Key exclusion criteria (4 listed)
- Patients treated outside of the approved Swiss label for Siponimod
- Prior treatment or already ongoing treatment with Siponimod
- Use of investigational drugs during the study, OR within 3 months before enrollment, OR within 5 half-lives of investigational drug before enrollment, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer
- Subjects who are not able to provide consent due to incapable judgement
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SiponimodProspective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled. | Other | Siponimod |
Primary outcome
Change of expanded disability status scale (EDSS)
Time frame: Baseline, month 36
The EDSS score is a widely used tool for determining the degree of disability in MS at any point in time. The EDSS value is generated based on overall impression and individual scores of the following functional systems: cognition, mood, fatigue, vision, brain stem, upper extremities, lower extremities, bladder and bowel function, sexuality. This results in a scale from 0 (healthy) to 10 (death from MS)
7 secondary outcomes
Proportion of patients with six month confirmed disability progression (CDP) by expanded disability status scale (EDSS)
Time frame: month 36
Proportion of patients with six month confirmed disease progression by symbol digit modalities test (SDMT)
Time frame: Up to 36 months
Treatment effect of Siponimod on walking speed as measured by the timed 25 foot walk test (T25FWT)
Time frame: Baseline, up to 36 months
Treatment effect of Siponimod on quality of life based on EQ-5D
Time frame: Baseline, month 36
Treatment effect of Siponimod on fatigue measured by Fatigue Scale for Motor and Cognitive Functions (FSMC)
Time frame: Baseline, month 36
Treatment effect of Siponimod on fatigue measured by Beck's depression inventory (BDI)
Time frame: Baseline, month 36
Treatment effect of Siponimod on fatigue measured by Epworth sleepiness scale (ESS) questionnaire
Time frame: Baseline, month 36
Results and safety
The study was stopped early (reason given: Insufficient patient recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Aug 2023.
- Individual participant dataSharing planned: No
Related trials for Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Primary Progressive Multiple Sclerosis, Primary Progressive MS
RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceiticals study director
Novartis Pharmaceuticals
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity, run by Novartis Pharmaceuticals at 6 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 29 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Insufficient patient recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of expanded disability status scale (EDSS) (time frame: Baseline, month 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2023.